Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about LONA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Fosgonimeton Sodium (ATH-1017) | Alzheimer Disease | Phase 2/3 · NCT04488419 | Completed |
| [14C]-Fosgonimeton | Healthy Volunteers | Phase 1 · NCT05511558 | Completed |
| ATH-1020 | Healthy Volunteers | Phase 1 · NCT05169671 | Completed |
| ATH-1105 | Healthy Volunteers | Phase 1 · NCT06432647 | Completed |
Also used in these trials (approved or third-party drugs, not LONA's own candidates): Abemaciclib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
LONA holds $51.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $18.9M/quarter from operations, an estimated runway of 8.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 85 · High
Based upon the Company’s current operating plan, it estimates that its $ 32.3 million of cash, cash equivalents and investments at September 30, 2026 will not be sufficient to fund its operating expenses and capital expenditure requirements under its current operating plan for at least the next 12 months, which raises…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LONA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| David J. Portman 10% owner |
Insider | 3,149,470 | 24.09% | 2026-10-26 |
| Sermonix Pharmaceuticals, Inc. | 5%+ holder (13D) | 3,149,470 | 24.09% | 2026-10-26 |
| Joseph Edelman | 5%+ holder (13D) | 1,869,050 | 14.29% | 2025-12-23 |
| Anders Hove | 5%+ holder (13G) | 1,492,521 | 11.41% | 2026-08-18 |
| ADAR1 Capital Management, LLC | Institution (13G, 5%+) | 727,481 | 5.56% | 2026-03-31 |
| Great Point Partners, LLC | Institution (13G, 5%+) | 474,345 | 3.63% | 2026-10-28 |
| PERCEPTIVE ADVISORS LLC Director, 10% owner · +3.78M options |
Insider | 329,756 | 2.52% | 2026-10-26 |
| Mark James Litton PRESIDENT and CEO, Director · +750,000 options |
Insider | 59,894 | 0.46% | 2026-03-03 |
| Kevin Church CHIEF SCIENTIFIC OFFICER · +300,000 options |
Insider | 25,178 | 0.19% | 2026-03-03 |
| Mark Worthington GENERAL COUNSEL and CCO · +300,000 options |
Insider | 18,376 | 0.14% | 2026-03-03 |
| Martin Javier San CHIEF MEDICAL OFFICER · +350,000 options |
Insider | 15,887 | 0.12% | 2026-03-03 |
| Robert Renninger CHIEF FINANCIAL OFFICER · +300,000 options |
Insider | 15,851 | 0.12% | 2026-03-03 |
Share count 13,076,348 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LONA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →